OncoPrecision is a pioneering startup in the field of precision oncology, aiming to revolutionize cancer treatment by moving away from the traditional one-size-fits-all approach. The company has developed a unique flow-cytometry-based co-culture screening technology for drug discovery, which is essentially a method to test the effectiveness of drugs on cancer cells. This technology is used to explore a public kinase inhibitor set, which are drugs that block certain enzymes and can help stop the growth of cancer cells.

The company's primary offering is the Drug Activity and Resistance Test (DARTⓇ), which combines deep biology to replicate a patient's disease and artificial intelligence to accurately predict their response to a range of cancer therapies. This allows for a more personalized approach to cancer treatment, increasing the likelihood of a positive response.

OncoPrecision operates in the healthcare and biotechnology market, serving clients ranging from early-stage drug developers to clinics prescribing treatments. The company's business model is centered around partnerships throughout the drug development process, from initial discovery to prescription. It generates revenue through these partnerships, likely through service fees or licensing agreements for its technology.

The company was founded by Gastón, a former Assistant Professor & Researcher at the National University of Córdoba, who has a strong conviction that each person is unique and requires tailored care. Over the past five years, his team has made significant strides in developing phenotypic screening platforms to identify novel targets and drugs for cancer therapy.

Keywords: Precision Oncology, Personalized Medicine, Drug Discovery, Co-Culture Screening Technology, Kinase Inhibitor, Drug Activity and Resistance Test (DARTⓇ), Artificial Intelligence, Biotechnology, Healthcare, Phenotypic Screening.